赛尼可预防糖尿病的肥胖受试者(XENDOS)研究:一项随机研究的奥利司他作为一个兼职改变生活方式预防2型糖尿病的肥胖病人。

文章的细节

引用

复制到剪贴板

Torgerson JS、Hauptman J Boldrin MN, Sjostrom L

赛尼可预防糖尿病的肥胖受试者(XENDOS)研究:一项随机研究的奥利司他作为一个兼职改变生活方式预防2型糖尿病的肥胖病人。

糖尿病护理。2004年1月,27 (1):155 - 61。

PubMed ID

14693982 (在PubMed

]

文摘

目的:完善,患2型糖尿病的风险的存在和持续时间密切相关超重和肥胖。减少2型糖尿病的发病率与生活方式的改变此前被证实。我们假设不错代理添加到生活方式的改变可能会导致一个更大的体重减少,因此2型糖尿病的发病率,在肥胖病人。研究设计和方法:在一个四年,双盲、前瞻性研究中,3305名患者随机改变生活方式+奥利司他120毫克或安慰剂,每日三次。参与者体重指数> / = 30 kg / m2和正常(79%)或(21%)糖耐量受损(IGT)。主要终点是2型糖尿病的发病时间和体重的变化。由意图治疗分析。结果:orlistat-treated患者中,52%完成了治疗与安慰剂组的34% (P < 0.0001)。经过4年的治疗,糖尿病的累积发病率与奥利司他与安慰剂9.0%和6.2%,相应的风险减少37.3% (P = 0.0032)。探索性分析表明,预防效果与IGT解释为主题的差异。 Mean weight loss after 4 years was significantly greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat recipients with impaired (5.7 kg) or normal glucose tolerance (NGT) (5.8 kg) at baseline. A second analysis in which the baseline weights of subjects who dropped out of the study was carried forward also demonstrated greater weight loss in the orlistat group (3.6 vs. 1.4 kg; P < 0.001). CONCLUSIONS: Compared with lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years and produced greater weight loss in a clinically representative obese population. Difference in diabetes incidence was detectable only in the IGT subgroup; weight loss was similar in subjects with IGT or NGT [correction].

beplay体育安全吗DrugBank数据引用了这篇文章

药物

奥利司他